terazosin / Generic mfg. - LARVOL DELTA

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

GLANCE-aided snapshotting for sustainable integration of synchronous spectrofluorimetry and micellar boosting for nanoscale assay of tolterodine binary mixtures in crucial matrices. (PubMed, Sci Rep) - "Tolterodine tartrate (TLD) has recently demonstrated remarkable synergism when combined with either of two α1-adrenergic antagonists, doxazosin mesilate (DXZ) or terazosin hydrochloride dihydrate (TRZ), for treating urinary tract issues. The outcomes demonstrated the excellence of the designed methodology over reported approaches, offering proficient sensitivity, sustainability, facility, and practicability across diverse crucial matrices. These findings provide compelling evidence that the proposed work serves as an efficient, eco-friendly quantification tool for use in quality control, biological, and environmental sectors, fostering a more eco-conscious and sustainable scientific community."

Journal

Non-Catalytic Inhibitors of the p38/MK2 Interface: Repurposing Approved Drugs to Target Neuroinflammation in Alzheimer's Disease. (PubMed, J Med Chem) - "Virtual screening of FDA-approved drugs prioritized nilotinib, a BCR-ABL inhibitor, as a putative PPI disruptor...Guided by these findings, we developed a lysate-based TR-FRET ultrahigh-throughput assay that identified additional inhibitors, including α1-adrenergic antagonists doxazosin, terazosin, and alfuzosin. These compounds suppressed cytokine induction via docking groove blockade. Together, these results establish a non-ATP-competitive approach for selectively targeting the p38/MK2 complex and highlight the translational potential of drug repurposing to modulate neuroinflammation in Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • ABL1 • BCR

APOE4 Reduces Glycolytic Enzymes and Sodium Potassium Pump to Enhance Seizure Susceptibility (AES 2025) - "A subset of APOE4 and APOE4/PS19 mice were treated with terazosin (1 mg/kg) with/out sodium oxamate (1 g/kg) prior to KA injections... APOE4 induced an age-dependent increase in seizure susceptibility, along with reduced hippocampal expression of Na⁺/K⁺-ATPase and glycolytic enzymes, as well as decreased ATP levels. These findings suggest that disruption of the electrochemical gradient and impaired ATP production contribute to the APOE4-associated rise in seizure susceptibility."

Late-breaking abstract • Alzheimer's Disease • CNS Disorders • Dementia • Epilepsy • APOE

Not Just One Answer: A Case of Resistant Hypertension with Overlapping Etiologies (KIDNEY WEEK 2025) - "Despite adherence to a low sodium diet, CPAP and a six-drug regimen including amlodipine 10mg, metoprolol 150mg, lisinopril 40mg, terazosin 20mg, chlorthalidone 25mg, and spironolactone 25mg daily, BP remained elevated at 160-180/80-90 mm Hg...He remained on metoprolol ER 50mg, diltiazem 240mg, furosemide 20mg daily for his hypertrophic cardiomyopathy...A concurrent renal artery stenosis was managed with angioplasty that helped bring his BP to goal. With this case, we highlight the importance of identifying and understanding the pathophysiology of secondary causes of resistant hypertension."

Clinical • Cardiomyopathy • Cardiovascular • Endocrine Disorders • Hypertension • Hypertrophic Cardiomyopathy • Nephrology • Renal Calculi

Pgk1 activation restores endothelial metabolic homeostasis to alleviate vascular aging and atherosclerosis. (PubMed, Cardiovasc Diabetol) - "Terazosin (TZ), a well-known antagonist of the α1-adrenergic receptor (α1-AR), has demonstrated protective effects on vascular endothelial cells (ECs) and reduced vascular stiffness in clinical studies...TZ effectively reversed these changes. Overall, our study demonstrates that TZ primarily alleviates EC senescence and atherosclerosis through the Pgk1/Hsp90/Prdx1 pathway, highlighting Pgk1 activation as a strategy that may also mitigate endothelial dysfunction and oxidative stress in broader cardiometabolic contexts (e.g., diabetes), suggesting that TZ is a promising senomorphic agent for treating vascular aging and atherosclerosis in clinical settings and that Pgk1-targeted interventions could have implications beyond atherosclerosis."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Metabolic Disorders • APOE • CDC37 • HSP90AA1 • PGK1 • PRDX1

TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: University of Iowa

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity."

Journal • Cardiovascular • Hypertension • Hypotension • Myocardial Infarction • Pain

EJS ACT-PD: Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial (clinicaltrials.gov) - P3 | N=1200 | Recruiting | Sponsor: University College, London

New P3 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Targeting MGLL: Terazosin Regulates Glycerolipid Metabolism to Mitigate Endothelial Cell Senescence. (PubMed, J Lipid Res) - "TZ directly bound to MGLL and inhibited its enzymatic activity, thereby mitigating PA-driven endothelial senescence. Collectively, these findings identify MGLL as a novel metabolic driver of endothelial senescence and establish TZ as a potential therapeutic agent for age-related vascular diseases."

Journal • Cardiovascular • Metabolic Disorders

TRAM: Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Penang Hospital, Malaysia | Not yet recruiting ➔ Recruiting

Enrollment open

A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults. (PubMed, J Parkinsons Dis) - "Our data show that TZ increases markers of energy metabolism with a biphasic dose-response and suggest that 5 mg/day TZ may provide maximal benefit while minimizing adverse consequences of higher doses. These results lay groundwork for clinical trials in people with PD."

Journal • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Microneedle-assisted iontophoretic transdermal administration of adrenergic antagonists does not modulate palmar sweating induced by static exercise in healthy young adults. (PubMed, Auton Neurosci) - "The efficacy of terazosin and propranolol on the palm was assessed by administering α- and β-adrenergic agonists (phenylephrine and salbutamol combined with aminophylline, respectively) in follow-up studies, whereas bretylium efficacy was verified by evaluating cold-induced palmar cutaneous vasoconstriction. The bretylium administration effectively abolished cold-induced cutaneous vasoconstriction (P = 0.006). In conclusion, this study demonstrates that transdermal administration of bretylium, terazosin, and propranolol does not alter palmar sweating induced by IKE exercise, implying the absence of adrenergic modulation."

Journal

ATF3 Deficiency Exacerbates Ageing-Induced Atherosclerosis and Clinical Intervention Strategy. (PubMed, Adv Sci (Weinh)) - "Terazosin (TZ) diminishes the interaction between YTH N6-methyladenosine RNA binding protein F2 (YTHDF2) and Atf3 mRNA, helping to preserve Atf3 mRNA stability...ATF3 protects against VSMC senescence and AS by orchestrating autophagy via a novel ATF3-ATG7 amplification loop. Repurposing TZ to stabilize ATF3 offers a translatable approach to combat ageing-driven cardiovascular disease."

Journal • Atherosclerosis • Cardiovascular • ATF3 • ATG7 • YTHDF2

Do transdermal administration of α1 and α2 adrenergic receptor antagonists modulate sweating in exercising young females in the heat? (PubMed, Skin Pharmacol Physiol) - "Sweat rates (ventilated capsule technique) on both forearms were assessed following pre-treatment with terazosin (α1-adrenergic receptor antagonist), rauwolscine (α2-antagonist), or control (NaCl) using transdermal iontophoresis procedure. Rauwolscine effectively abolished clonidine-induced cutaneous vasoconstriction in a follow-up study, verifying successful transdermal delivery. Conclusion The α₁- and α₂-adrenergic receptors do not alter sweating during moderate-intensity exercise in males and females, at least among individuals with relatively low sweat production."

Journal

Tetrahydrofuran-containing Pharmaceuticals: Targets, Pharmacological Activities, and Their SAR Studies. (PubMed, ChemMedChem) - "The US Food and Drug Administration (FDA) has approved a total of 13 drugs for a range of clinical diseases， such as Terazosin and Darunavir. These drugs exhibit superior pharmacological effects in multiple therapeutic fields. This review offers an extensive overview of FDA-approved drugs containing the tetrahydrofuran nucleus, emphasizing their pharmacological activities and structure-activity relationships."

Journal

New Lead Schiff Bases Predominantly Mediate Vasorelaxant Activity Through α1 Receptor Blocking Activity. (PubMed, Biomolecules) - "Terazosin served as a standard α1 receptor blocker...Additive effects of SB1 and SB2 were seen in the presence of verapamil (p < 0.0001). Docking analysis revealed that the compounds can properly bind to the target receptor Gq 1D (P25100). Findings show that both Schiff base SB1 and SB2 produce significant (p < 0.05) vasorelaxation via the α1 receptor blocking mechanism."

Journal • Gastrointestinal Disorder • Pain

Managing Page Kidney in a Patient With Underlying Renal Cell Carcinoma: A Case Report (ATS 2025) - "Blood pressure stabilized with adjusted medication, and he was discharged on five anti-hypertensives (Amlodipine, Hydralazine, Losartan, Metoprolol and Terazosin). If medical management fails, surgical intervention such as capsulotomy, hematoma evacuation, or nephrectomy may be necessary, particularly for large or expanding hematomas. Optimal outcomes are achieved through multidisciplinary management involving Urology, Nephrology, and Interventional Radiology."

Case report • Clinical • Acute Kidney Injury • Autism Spectrum Disorder • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Genetic Disorders • Genito-urinary Cancer • Hematological Disorders • Hypertension • Nephrology • Oncology • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Urology

TRAM: Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (clinicaltrials.gov) - P3 | N=150 | Not yet recruiting | Sponsor: Penang Hospital, Malaysia

New P3 trial

Evaluation of Additive Neuroprotective Effect of Combination Therapy for Parkinson's Disease Using In Vitro Models. (PubMed, Antioxidants (Basel)) - "We demonstrated that some of the medications, used in combination, can exert an additive neuroprotective effect in preclinical models of PD that is superior to that of each of the compounds individually. This project can lead to the development of the first treatment for PD that can slow or prevent its progression."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • NEFH

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform. (PubMed, Mov Disord) - "Drug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives."

Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

Glycolysis-enhancing α1-adrenergic antagonists are neuroprotective in Alzheimer's disease. (PubMed, bioRxiv) - "Terazosin (TZ) is an α 1 -adrenergic receptor antagonist that enhances glycolysis by activating the enzyme phosphoglycerate kinase 1 (PGK1). Finally, in a large human administrative dataset, we found that patients taking TZ or related glycolysis-enhancing drugs had a lower hazard of being diagnosed with AD compared to those taking tamsulosin or 5-alpha reductase inhibitors. These data further implicate metabolism in neurodegenerative diseases and suggest that glycolysis-enhancing drugs may be neuroprotective in AD."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Parkinson's Disease • Solid Tumor • PGK1

Phosphoglycerate kinase 1 as a therapeutic target in neurological disease. (PubMed, Trends Mol Med) - "This review examines recent evidence that suggests increasing PGK1 activity may be beneficial in multiple neurological conditions and discusses the current challenges surrounding the development of PGK1-focused therapies. PGK1 has considerable therapeutic potential, but novel PGK1 activators are needed to maximize the benefit for patients."

Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Genetic Disorders • Movement Disorders • Parkinson's Disease • Rare Diseases • PGK1

Extended multidimensional design space studies: Comparing volatile and non-volatile buffer systems in UPLC. (PubMed, J Chromatogr A) - "To explore this, we utilized an Analytical Quality by Design (AQbD) modeling approach with DryLab to construct and compare three-dimensional (tG-T-pH) separation models for terazosin and selected impurities across a pH range of 6.0-8.0. These Design Space (DS) models provided a comprehensive understanding of the dynamic changes occurring within each separation system. Notably, our findings revealed not only equivalent separation performance, as indicated by overlapping Method Operable Design Regions (MODRs), but also critical insights into buffer-specific differences in the selectivity of HPLC-separations."

Journal